Authors
Latest:
Optimizing Use of PSMA PET Imaging and PSADT in Prostate CancerShared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.
Latest:
Dr. Razis on the Significance of TERT in the Presence of NF1 in GBMEvangelia Razis, MD, PhD, medical oncologist, Hygeia Hospital, Athens, Greece, discusses the significance of TERT mutations in the presence of NF1 mutations in patients with glioblastoma (GBM).
Latest:
Dr. Roussos Torres on the Importance of Preclinical Models in HER2+ Breast CancerEvanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.
Latest:
Dr. Vokes Discusses Unanswered Questions from the PACIFIC Trial in NSCLCEverett E. Vokes, MD, discusses unanswered questions from the phase III PACIFIC trial in stage III non–small cell lung cancer.
Latest:
Preview of ASCO 2022: Dr Everett VokesOncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Dr. Stein on the KOMET-001 Trial in Relapsed/Refractory AMLEytan M. Stein, MD, discusses the phase 1/2 KOMET-001 trial in relapsed/refractory acute myeloid leukemia.
Latest:
Dr Stein on the Development of Targeted Therapies in Splicing Mutant Hematologic MalignanciesEytan M. Stein, MD, discusses the ongoing development and investigation of therapies targeting splicing mutations in hematologic malignancies.
Latest:
Dr. Cohen on Future Research Directions in Head and Neck CancerEzra Cohen, MD, FRCPSC, FASCO, discusses future research directions for the treatment of patients with head and neck cancer.
Latest:
Sequencing Throughout Multiple Lines of Therapy in RR DTCBefore closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.
Latest:
Dr. Elhassadi on the Subtypes of MCLEzzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses the subtypes of mantle cell lymphoma (MCL).
Latest:
Focal Therapy Evolves Into More Precise Treatment in Prostate CancerHistorically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.
Latest:
Dr. Hodi on Long-Term Survival Data for Nivolumab in MelanomaF. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, discusses the results of the longest follow-up survival study of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).
Latest:
Dr. Andre on the Impact of the SOLAR-1 Findings in Breast CancerFabrice André, MD, PhD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the impact of the SOLAR-1 findings in breast cancer at the 2018 ESMO Congress.
Latest:
Dr. Andre on Strategies to Improve Outcomes in Breast CancerFabrice André, MD, PhD, discusses strategies to improve outcomes in patients with breast cancer.
Latest:
Do We Still Need Physical Exams in the Era of Advanced Imaging Technologies?Throughout fellowship, my experiences working with patients in clinic have taught me many lessons.
